Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | AstraZeneca AB | 1,110 |
| 2 | Merck Sharp & Dohme LLC | 1,096 |
| 3 | Novartis AG | 1,052 |
| 4 | Boehringer Ingelheim International GmbH | 867 |
| 5 | Glaxo Group Ltd | 757 |
| 6 | Procter and Gamble Co | 512 |
| 7 | Massachusetts Institute of Technology | 504 |
| 8 | Kenvue Brands LLC | 425 |
| 9 | AbbVie Inc | 419 |
| 10 | Ono Pharmaceutical Co Ltd | 355 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61P | Therapeutic activity (drug indications) | 25,867 |
| 2 | A61K | Medicinal preparations | 25,376 |
| 3 | C07D | Heterocyclic compounds | 13,716 |
| 4 | C07K | Peptides | 3,597 |
| 5 | C12N | Microorganisms, enzymes | 2,297 |
| 6 | A61M | Devices for introducing media into the body | 2,153 |
| 7 | Y02A | Climate change adaptation | 1,971 |
| 8 | C07C | Acyclic and carbocyclic compounds | 1,930 |
| 9 | G01N | Investigating / analysing materials | 1,390 |
| 10 | A61Q | Cosmetics, personal care | 1,200 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionMost-cited patents
Patents ranked by forward citations reveal the foundational inventions the field continues to build on.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| Combination dosage form comprising cetirizine and pseudoephedrine | 2001 | Kenvue Brands LLC | 60 |
| Methods and compositions using cetirizine in combination with leukotriene inhibitors or decongestants | 2002 | Sumitomo Pharma America Inc | 45 |
| Solid, rapidly disintegrating cetirizine formulations | 2001 | Meda Pharma GmbH and Co KG | 43 |
| CETIRIZINE-CONTAINING COMPOSITION FOR ANTIALLERGIC EYE DROP AND NASAL DROP | 1994 | Senju Pharmaceutical Co Ltd | 40 |
| Methods for treating allergic disorders using optically pure (-) cetirizine | 1997 | Sumitomo Pharma America Inc | 39 |
Where research is gaining momentum
Research themes ranked by publication activity show where scientific interest is accelerating around this compound.
| # | Research topic | Papers |
|---|---|---|
| 1 | Allergic Rhinitis and Sensitization | 22 |
| 2 | Asthma and respiratory diseases | 7 |
| 3 | Urticaria and Related Conditions | 6 |
| 4 | Dermatology and Skin Diseases | 4 |
| 5 | Analytical Chemistry and Chromatography | 3 |
| 6 | Analytical Methods in Pharmaceuticals | 3 |
| 7 | Drug-Induced Adverse Reactions | 3 |
| 8 | Cardiac electrophysiology and arrhythmias | 2 |
| 9 | Drug Transport and Resistance Mechanisms | 2 |
| 10 | Mast cells and histamine | 2 |
Technology trend analysis
Cypris uses AI to connect emerging research themes to IP activity, commercialization signals, and underexplored opportunity areas.
See Cypris in actionWho's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | J.‐P. Rihoux | UCB Pharma (Belgium) | 18 |
| 2 | Giorgio Ciprandi | Ospedale Policlinico San Martino | 11 |
| 3 | F. Estelle R. Simons | University of Manitoba | 9 |
| 4 | Giorgio Walter Canonica | University of Genoa | 10 |
| 5 | Bernard Burtin | UCB Pharma (Belgium) | 9 |
| 6 | Garry M. Walsh | University of Aberdeen | 6 |
| 7 | Andrew M. Wilson | University of Dundee | 5 |
| 8 | Annemiek Vermeeren | Maastricht University | 5 |
| 9 | Antonio Valero | Hospital Clínic de Barcelona | 5 |
| 10 | Ashok Purohit | Inserm | 5 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Contamination of surface, ground, and drinking water from pharmaceutical production | 2009 | 1100 | Analytical chemistry methods development |
| Allergic Rhinitis | 2015 | 585 | Allergic Rhinitis and Sensitization |
| Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis | 2004 | 501 | Asthma and respiratory diseases |
| Statistical significant change versus relevant or important change in (quasi) experimental design: some conceptual and methodological problems in estimating magnitude of intervention-related change in health services research | 2002 | 473 | Health Policy Implementation Science |
| The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria | 2010 | 328 | Dermatology and Skin Diseases |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular formula and weight of cetirizine?
Which organizations hold the most patents related to cetirizine?
What are the main research topics associated with cetirizine?
What formulation innovations have been patented for cetirizine?
Who are the most prolific authors publishing on cetirizine research?